Bavarian Nordic A/S (OTCMKTS:BVNRY) Downgraded by Zacks Investment Research

Bavarian Nordic A/S (OTCMKTS:BVNRYGet Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Tuesday, reports.

According to Zacks, “Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company’s product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark. “

Separately, Cowen downgraded Bavarian Nordic A/S from an “outperform” rating to a “market perform” rating in a research note on Friday, February 4th.

Shares of OTCMKTS BVNRY remained flat at $$7.35 during trading on Tuesday. 654 shares of the company’s stock traded hands, compared to its average volume of 748. Bavarian Nordic A/S has a 52 week low of $7.33 and a 52 week high of $19.25. The stock has a 50-day moving average price of $8.61 and a two-hundred day moving average price of $12.02.

Bavarian Nordic A/S (OTCMKTS:BVNRYGet Rating) last released its quarterly earnings results on Friday, March 4th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.03). The firm had revenue of $83.65 million during the quarter, compared to analyst estimates of $93.33 million. As a group, equities research analysts forecast that Bavarian Nordic A/S will post -1.03 earnings per share for the current year.

Bavarian Nordic A/S Company Profile (Get Rating)

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.

Further Reading

Get a free copy of the Zacks research report on Bavarian Nordic A/S (BVNRY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Bavarian Nordic A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic A/S and related companies with's FREE daily email newsletter.